Please share...
The US Food and Drug Administration approved a treatment Friday for a genetic disease called spinal muscular atrophy that causes infants’ muscles to waste away, potentially killing them before age 2.
Gene therapy gets FDA approval — and a $2 million price tag
May 26, 2019By
